<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03072056</url>
  </required_header>
  <id_info>
    <org_study_id>MIN-101C05</org_study_id>
    <nct_id>NCT03072056</nct_id>
  </id_info>
  <brief_title>A Pharmacokinetic Study of MIN-101 and Its Metabolites in Healthy Subjects to Compare MIN-101 in Poor and Extensive Metabolizers</brief_title>
  <official_title>A Phase 1, Open-Label, 3-Period, Single-Ascending Dose, Crossover Study in Healthy Subjects to Compare PK Properties of MIN-101 and Its Metabolites Poor and Extensive Metabolizers as Defined by Cytochrome P450 2D6 Genotype</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Minerva Neurosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Minerva Neurosciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  To evaluate the pharmacokinetic (PK) profile of MIN-101 and its metabolites in extensive
           (EM) and poor (PM) metabolizers

        -  To evaluate the relationship between plasma levels of MIN-101 and changes in QT/QTcF
           intervals

        -  To evaluate safety and tolerability of MIN-101.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 9, 2017</start_date>
  <completion_date type="Actual">July 7, 2017</completion_date>
  <primary_completion_date type="Actual">July 7, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma PK parameter, Cmax</measure>
    <time_frame>0, .25, .5, .75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 14, 16, 24, 28, 32, 36, 48, 52, 56, 60, 72, and 76 hr post-dose on Day 1 of 3 periods (each period is up to 6 days). One sample from PM subjects at hr 98±2</time_frame>
    <description>To estimate the relative bioavailability of MIN-l0l following MIN-101 administration. Plasma samples will be analyzed for MIN-101 and its metabolites using a validated LC-MS/MS method</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma PK parameter, Tmax</measure>
    <time_frame>from predose up to 76 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma PK parameter, Tlag</measure>
    <time_frame>from predose up to 72 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma PK parameter,partial AUC (e.g., AUC12, AUC24), AUClast, AUC∞</measure>
    <time_frame>from predose up to 72 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma PK parameter, λz and t1/2</measure>
    <time_frame>from predose up to 72 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the relationship between plasma levels of MIN-101 and its main metabolites and changes in QT/QTcF intervals in healthy CYP2D6 EM and PM subjects</measure>
    <time_frame>at -1.5, -1, -0.25 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, 24, 28, 32, 36, 48, 56, 72, and 76 hours post-dose on Day 1 of the 3 periods (each period is up to 6 days).</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety (AE reporting, safety laboratory parameters analysis, vital signs and 12 lead ECG assessments)</measure>
    <time_frame>3 months and 7 days</time_frame>
    <description>Safety will be assessed through AE reporting, safety laboratory parameters analysis, vital signs and 12 lead ECG assessments</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Extensive Metabolizers, 4 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects will receive 32 mL of MIN-101 as a 0.125 mg/mL oral solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Extensive Metabolizers, 8 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects will receive 32 mL of MIN-101 as a 0.25 mg/mL oral solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Extensive Metabolizers, 16 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects will receive 32 mL of MIN-101 as a 0.5 mg/mL oral solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Poor Metabolizers, 4 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects will receive 32 mL of MIN-101 as a 0.125 mg/mL oral solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Poor Metabolizers, 8 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects will receive 32 mL of MIN-101 as a 0.25 mg/mL oral solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Poor Metabolizers, 16 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects will receive 32 mL of MIN-101 as a 0.5 mg/mL oral solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MIN-101</intervention_name>
    <arm_group_label>Extensive Metabolizers, 4 mg</arm_group_label>
    <arm_group_label>Extensive Metabolizers, 8 mg</arm_group_label>
    <arm_group_label>Extensive Metabolizers, 16 mg</arm_group_label>
    <arm_group_label>Poor Metabolizers, 4 mg</arm_group_label>
    <arm_group_label>Poor Metabolizers, 8 mg</arm_group_label>
    <arm_group_label>Poor Metabolizers, 16 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Confirmed CYP2D6 extensive or poor metabolizer genotype

          2. Subject has given voluntary written informed consent before performance of any study
             related procedure

          3. Subject must be 18 to 45 years of age, inclusive

          4. Subject must be a healthy male or female as indicated by the following:

               -  Clinical chemistries, hematology, and urinalysis tests must be within normal,
                  allowable limits (if out of range, and with the exception of potassium,
                  magnesium, and calcium, must be considered clinically significant to be
                  exclusionary) and performed within 21 days of receiving first dose of study drug

               -  Body mass index of between 18 and 30 kg/m2

               -  Normal vital signs after 5 minutes resting in supine position and in standing
                  position after 5 minutes of resting in supine position:

                    -  95 mm Hg &lt; systolic blood pressure &lt; 140 mm Hg

                    -  50 mm Hg &lt; diastolic blood pressure &lt; 90 mm Hg

                    -  50 bpm &lt; heart rate &lt; 90 bpm

                    -  Systolic blood pressure decrease of less than 20 mm Hg within 3 minutes of
                       standing

                    -  Diastolic blood pressure decrease of less than 10 mm Hg within 3 minutes of
                       standing

               -  Normal 12-lead automatic ECG: 120 ms &lt; PR &lt; 210 ms, QRS &lt; 120 ms, QTc
                  (Fridericia) ≤ 430 msec for males and ≤ 440 ms for females

          5. Agree to abstain from all medication (except for allowed birth control in #5 below),
             including non-prescription and prescription medication (including vitamins and natural
             or herbal remedies, e.g. St. John's Wort) for 21 days before the first study day until
             discharge from the study (end of post study medical).

          6. Subject agrees to use an adequate method of birth control (excluding oral hormonal
             contraception). Subjects who are sexually active must use, with their partner, 2
             approved methods of highly effective contraception from the time of study drug
             administration until 90 days after the last dose of study drug.

        Exclusion Criteria:

          1. A history of clinically significant gastrointestinal disease, especially peptic
             ulcerations, gastrointestinal bleeding, ulcerative colitis, Crohn's disease or
             Irritable Bowel Syndrome; renal, hepatic, neurologic, hematologic, endocrine,
             oncologic, pulmonary, immunologic or psychiatric disease, especially those with a past
             history of depression, suicidal ideation or suicide attempts, or cardiovascular
             disease, or any other condition which, in the opinion of the principle investigator,
             would jeopardize the safety of the subject or impact the validity of the study results

          2. Acute diarrhea or constipation in the 7 days before the predicted first study day. If
             screen occurs &gt; 7 days before first study day, this criterion will be determined on
             first study day.

          3. Subject has donated blood within 90 days or plasma within 30 days of study dosing

          4. Regular alcohol consumption in males &gt; 21 units per week and females &gt; 14 units per
             week (1 Unit = ½ pint beer, 25 mL of 40% spirit or a 125 mL glass of wine)

          5. Subject has a borderline or long QTc interval by the Fridericia correction method, as
             defined by screening readings of &gt; 430 msec for males and &gt; 440 for females or a
             personal or familial history of long QT syndrome

          6. Subject has participated in a clinical trial within 90 days prior to study initiation

          7. Females of child bearing potential who are pregnant, breast feeding or who are either
             not surgically sterile, postmenopausal, or are sexually active and not using an
             acceptable form of contraception

          8. Subject has used any over-the-counter (OTC) medication, dietary or herbal supplements,
             including vitamins, within 21 days prior to study entry

          9. Subject has used any prescription medication within 21 days prior to the Day -1

         10. Subject has been treated with any known CYP2D6 or CYP3A4 enzymes altering drugs within
             30 days prior to the study

         11. Subject has smoked or used tobacco products within 2 months prior to or during the
             study

         12. Subject has sought advice from or been referred to a GP or counselor for abuse or
             misuse of alcohol, non-medical drugs, medicinal drugs or other substance abuse, e.g.

             solvents

         13. Subject has a positive blood screen for HIV, Hepatitis B surface antigen (HBsAg), and
             Hepatitis C antibody and/or a positive urine screen for drugs of abuse or positive
             alcohol breath test at screening, or history of positive urine drugs of abuse screens

         14. Any current or previous use of drugs such as opiates, cocaine, ecstasy, or intravenous
             amphetamines Subjects who admit to occasional past use of cannabis will not be
             excluded as long as they have a negative drugs-of-abuse test and have been abstinent
             from cannabis use for at least 3 months

         15. Subject has an uncontrolled inter-current illness (i.e., active infection)

         16. Subject has had major surgery within 28 days of study entry, or 12 months prior to
             study for gastrointestinal surgery.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Jabbari, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>BioKinetic Europe Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Biokinetic Europe</name>
      <address>
        <city>Belfast</city>
        <zip>BT2 7BA</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ireland</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2017</study_first_submitted>
  <study_first_submitted_qc>March 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 7, 2017</study_first_posted>
  <last_update_submitted>August 30, 2017</last_update_submitted>
  <last_update_submitted_qc>August 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

